Peer-influenced content. Sources you trust. No registration required. This is HCN.
The New England Journal of Medicine
In this study, dostarlimab combined with carboplatin-paclitaxel demonstrated a marked improvement in progression-free and overall survival among endometrial cancer patients, particularly those with genetic markers for dMMR and MSI-H.
Obstetrics & Gynecology April 18th 2024
OBR Oncology
Explore this development in metastatic melanoma treatment with the FDA’s accelerated approval of TIL therapy, a promising approach for patients who have exhausted other options.
Hematology/Oncology April 8th 2024
Cancer Therapy Advisor
Explore new horizons in advanced hepatocellular carcinoma treatment with emerging data on lenvatinib and cisplatin’s potential efficacy as a second-line therapy and the promising triple combination therapy showing significant response rates.
Oncology, Medical April 1st 2024
Explore the potential of CARv3-TEAM-E T cells in recurrent glioblastoma, a novel therapy showing promise with rapid tumor regression and no severe adverse effects in early clinical evaluation.
Oncology, Medical March 18th 2024
Clinical Advances in Hematology & Oncology
Epcoritamab represents a significant breakthrough in the treatment of Richter syndrome, showcasing promising results in patients who have exhausted other therapeutic avenues. Its unique bispecific action heralds a new era in hematologic malignancy management.
Hematology/Oncology March 18th 2024
This pivotal study demonstrates that the combination of enfortumab vedotin and pembrolizumab not only extends progression-free survival but also significantly improves overall survival rates in patients with untreated advanced urothelial carcinoma.
Oncology, Medical March 11th 2024